AbbVie beat Q2 earnings estimates fueled by Botox demand revival, sending shares higher.
A16z-backed Braveheart seeks $318.8 million in a US IPO, signaling continued vigor in the venture-backed biotech market.
Goldman Sachs-backed biotech firm Attovia is seeking $212.5 million in a US IPO, signaling ongoing appetite for healthcare listings amid cautious equity…
FTC and Utah's lawsuit against Hims & Hers Health sends shares sharply lower, raising red flags for the entire telehealth sector.
Shionogi-backed biotech Apnimed seeks to raise $160 million in a US IPO, highlighting investor appetite for sleep disorder treatments and cross-border healthcare…
Philips' Q2 results surpassed estimates with a tailwind from a US tariff refund, though underlying demand trends remain uneven.
Trump’s tariff threat on pharmaceutical imports raises fears of generic drug shortages, hitting pharma stocks and potentially strengthening the US dollar amid…
Biotech IPOs lead US markets in 2026, outpacing AI listings as healthcare innovation takes center stage over artificial intelligence.
IG4 Capital pursues voting control of Oncoclinicas in a restructuring, aiming to consolidate power and influence the Brazilian healthcare chain's strategy.
Bristol-Myers Squibb teams up with Nvidia to create an AI factory for drug development, marking a major push into AI-driven pharmaceutical research.
Apnimed, backed by Japanese drugmaker Shionogi, files IPO to raise capital for Phase 3 trial of oral sleep apnea therapy, targeting a…
Bayer divests contraceptive division stake to Apollo in a €3 billion deal, boosting its balance sheet and refocusing its pharmaceutical strategy.